Human radiolabeled mass balance studies: objectives, utilities and limitations.
暂无分享,去创建一个
[1] D. Gurwitz,et al. CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies. , 2009, Pharmacogenomics.
[2] Philip Timmerman,et al. Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development. , 2009, Chemical research in toxicology.
[3] K. Pang,et al. Disparity in Intestine Disposition between Formed and Preformed Metabolites and Implications: A Theoretical Study , 2009, Drug Metabolism and Disposition.
[4] M. Morris,et al. Formed and preformed metabolites: facts and comparisons , 2008, The Journal of pharmacy and pharmacology.
[5] C. Prakash,et al. Metabolism, Pharmacokinetics, and Excretion of a Cholesteryl Ester Transfer Protein Inhibitor, Torcetrapib, in Rats, Monkeys, and Mice: Characterization of Unusual and Novel Metabolites by High-Resolution Liquid Chromatography-Tandem Mass Spectrometry and 1H Nuclear Magnetic Resonance , 2008, Drug Metabolism and Disposition.
[6] C. Prakash,et al. Disposition of Lasofoxifene, a Next-Generation Selective Estrogen Receptor Modulator, in Healthy Male Subjects , 2008, Drug Metabolism and Disposition.
[7] Leslie Z Benet,et al. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. , 2008, Advanced drug delivery reviews.
[8] Vinod P. Shah,et al. The Use of BDDCS in Classifying the Permeability of Marketed Drugs , 2008, Pharmaceutical Research.
[9] Steven R Tannenbaum,et al. Application of liquid chromatography-accelerator mass spectrometry (LC-AMS) to evaluate the metabolic profiles of a drug candidate in human urine and plasma. , 2007, Drug metabolism letters.
[10] Angus Nedderman,et al. Analytical strategies for identifying drug metabolites. , 2007, Mass spectrometry reviews.
[11] C. L. Shaffer,et al. Metabolism of a 14C/3H-labeled GABAA receptor partial agonist in rat, dog and human liver microsomes: evaluation of a dual-radiolabel strategy. , 2007, Journal of pharmaceutical and biomedical analysis.
[12] R. Obach,et al. What is the Objective of the Mass Balance Study? A Retrospective Analysis of Data in Animal and Human Excretion Studies Employing Radiolabeled Drugs , 2007, Drug metabolism reviews.
[13] Thomayant Prueksaritanont,et al. Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites. , 2006, Toxicology and applied pharmacology.
[14] R Scott Obach,et al. Metabolites and safety: What are the concerns, and how should we address them? , 2006, Chemical research in toxicology.
[15] Malcolm Rowland,et al. Use of microdosing to predict pharmacokinetics at the therapeutic dose: Experience with 5 drugs , 2006, Clinical pharmacology and therapeutics.
[16] C. L. Shaffer,et al. Using a Tritiated Compound to Elucidate Its Preclinical Metabolic and Excretory Pathways in Vivo: Exploring Tritium Exchange Risk , 2006, Drug Metabolism and Disposition.
[17] M. Jemal,et al. METABOLISM OF [14C]GEMOPATRILAT AFTER ORAL ADMINISTRATION TO RATS, DOGS, AND HUMANS , 2006, Drug Metabolism and Disposition.
[18] W. Richter,et al. The distribution pattern of radioactivity across different tissues in quantitative whole-body autoradiography (QWBA) studies. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[19] P. Sandin,et al. Introduction to early in vitro identification of metabolites of new chemical entities in drug discovery and development. , 2006, Pharmacological reports : PR.
[20] Joelle M. R. Gola,et al. Focus on success: using a probabilistic approach to achieve an optimal balance of compound properties in drug discovery , 2006, Expert opinion on drug metabolism & toxicology.
[21] Hua Yang,et al. EVALUATION OF MICRODOSING TO ASSESS PHARMACOKINETIC LINEARITY IN RATS USING LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY , 2006, Drug Metabolism and Disposition.
[22] J. Schellens,et al. Mass Balance Studies, with a Focus on Anticancer Drugs , 2006, Clinical pharmacokinetics.
[23] R Scott Obach,et al. SEEING THROUGH THE MIST: ABUNDANCE VERSUS PERCENTAGE. COMMENTARY ON METABOLITES IN SAFETY TESTING , 2005, Drug Metabolism and Disposition.
[24] Weiping Zhao,et al. Analysis of low level radioactive metabolites in biological fluids using high-performance liquid chromatography with microplate scintillation counting: method validation and application. , 2005, Journal of pharmaceutical and biomedical analysis.
[25] C. Prakash,et al. CHARACTERIZATION OF A NOVEL METABOLITE INTERMEDIATE OF ZIPRASIDONE IN HEPATIC CYTOSOLIC FRACTIONS OF RAT, DOG, AND HUMAN BY ESI-MS/MS, HYDROGEN/DEUTERIUM EXCHANGE, AND CHEMICAL DERIVATIZATION , 2005, Drug Metabolism and Disposition.
[26] David Q. Liu,et al. Strategies for characterization of drug metabolites using liquid chromatography-tandem mass spectrometry in conjunction with chemical derivatization and on-line H/D exchange approaches. , 2005, Journal of pharmaceutical and biomedical analysis.
[27] K. Brune,et al. Cytochrome P450 Polymorphisms in Geriatric Patients , 2005, Drugs & aging.
[28] M. P. Baker,et al. EVALUATION OF MICRODOSING STRATEGIES FOR STUDIES IN PRECLINICAL DRUG DEVELOPMENT: DEMONSTRATION OF LINEAR PHARMACOKINETICS IN DOGS OF A NUCLEOSIDE ANALOG OVER A 50-FOLD DOSE RANGE , 2004, Drug Metabolism and Disposition.
[29] A. Palmer,et al. The pivotal role of drug metabolism and pharmacokinetics in the discovery and development of new medicines. , 2004, IDrugs : the investigational drugs journal.
[30] Andrew M Davis,et al. Predictive ADMET studies, the challenges and the opportunities. , 2004, Current opinion in chemical biology.
[31] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[32] Y. Parmentier,et al. Liquid chromatography-accurate radioisotope counting and microplate scintillation counter technologies in drug metabolism studies. , 2004, Journal of chromatographic science.
[33] B. Hughey,et al. An interface for direct analysis of (14)c in nonvolatile samples by accelerator mass spectrometry. , 2004, Analytical chemistry.
[34] Matthew Segall,et al. In silico prediction of ADME properties: are we making progress? , 2004, Current opinion in drug discovery & development.
[35] Leslie Z. Benet,et al. Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System , 2004, Pharmaceutical Research.
[36] Abigail Jacobs,et al. Drug metabolites in safety testing. , 2003, Toxicology and applied pharmacology.
[37] G. Patonay,et al. High-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry. , 2003, Journal of pharmaceutical and biomedical analysis.
[38] T. Baillie,et al. Drug metabolites in safety testing. , 2002, Toxicology and applied pharmacology.
[39] E. Solon,et al. Quantitative whole-body autoradiography in the pharmaceutical industry. Survey results on study design, methods, and regulatory compliance. , 2001, Journal of pharmacological and toxicological methods.
[40] K A Bachmann,et al. The use of in vitro methods to predict in vivo pharmacokinetics and drug interactions. , 2001, Current drug metabolism.
[41] G. Bruin,et al. Use of a microplate scintillation counter as a radioactivity detector for miniaturized separation techniques in drug metabolism. , 2000, Analytical chemistry.
[42] L. Lesko,et al. Optimizing the Science of Drug Development: Opportunities for Better Candidate Selection and Accelerated Evaluation in Humans , 2000, Journal of clinical pharmacology.
[43] D. Tweedie,et al. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. , 2000, British journal of clinical pharmacology.
[44] C. Hop,et al. Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. , 1998, Journal of pharmaceutical sciences.
[45] The search for orally active medications through combinatorial chemistry , 1998, Medicinal research reviews.
[46] A. Clifford,et al. Protocol development for biological tracer studies. , 1998, Advances in experimental medicine and biology.
[47] K. Wilner,et al. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[48] C. Prakash,et al. Metabolism and excretion of the novel antipsychotic drug ziprasidone in rats after oral administration of a mixture of 14C- and 3H-labeled ziprasidone. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[49] R A Hamilton,et al. Determination of mean valproic acid serum level by assay of a single pooled sample , 1981, Clinical pharmacology and therapeutics.